產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-PARK7/CAP1抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢(xún)訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-PARK7/CAP1抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-PARK7/CAP1
Cat. Number:
Anti-PARK7/CAP1抗體KL-1306R
Quantity size:
0.1ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PARK7/DJ1 is a ubiquitously expressed protein involved in various cellular processes including cell proliferation, RNA-binding, and oxidative stress. The protein has been found to colocalize within a subset of pathologic tau inclusions in a diverse group of neurodegenerative disorders known as tauopathies (Rizzu et al. 2004). Defects in PARK7/DJ1 are the cause of autosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorial disorder that typically manifestsAnti-PARK7/CAP1抗體 after the age of 50 years. The disease is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK7 is characterized by onset before 40 years and slow progression. It has also been suggested that PARK7/DJ1 is a mitogen dependent oncogene product involved in Ras related signal transduction pathways.
Also known as:
PARK7; PARK-7; Parkinson disease Anti-PARK7/CAP1抗體protein 7; Park7 protein; CAP1; DJ-1; Dj1; DJ 1; SP22; Protein DJ-1; Oncogene DJ1; FLJ27376; Park 7; Parkinson disease (autosomal recessive early onset) 7; RNA binding protein regulatory subunit; RS; SP22; CAP1_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Pig, Cow, Horse, .
●
Immunogen: KLH conjugated Anti-PARK7/CAP1抗體synthetic peptide derived from human CAP1.
●
Predicted Molecular Weight: 20kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1: 50-200 IF=1:100-500
Not yet tested in other applications. Anti-PARK7/CAP1抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-PARK7/CAP1抗體
Optimal working dilutions must be determined by the end user.
